Advertisement
Screener

Stoke Therapeutics, Inc. (STOK) Graph

STOK Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $9.32M; Research and development $49.50M; Selling, general and administrative $25.25M; Operating expenses $74.75M.
  • 2026-03-31: Revenue $6.23M; Research and development $39.67M; Selling, general and administrative $19.97M; Operating expenses $59.65M.
  • 2025-12-31: Revenue $1.40M*; Research and development $41.70M*; Selling, general and administrative $21.15M*; Operating expenses $62.84M*.
  • 2025-09-30: Revenue $10.63M; Research and development $37.70M; Selling, general and administrative $16.03M; Operating expenses $53.72M.

Type Of Arrangement

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

STOK revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Acadia Agreement$2.80MBiogen LicenseAgreement$6.50MRevenue$9.32MOperating expenses$74.75MOperating income-$65.43MOther income, net$308.00KResearch & development$49.50MSelling, general& administrative$25.25MPre-tax income-$61.62MIncome tax$0.00Net income-$61.62M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2026-06-30$9.32M$49.50M$25.25M$74.75M$0.00-$61.62M
2026-03-31$6.23M$39.67M$19.97M$59.65M$0.00-$50.00M
2025-12-31$1.40M*$41.70M*$21.15M*$62.84M*$0.00*-$57.93M*
2025-09-30$10.63M$37.70M$16.03M$53.72M-$1.28M-$38.35M
2025-06-30$13.82M$25.86M$15.26M$41.12M$0.00-$23.48M
2025-03-31$158.57M$32.68M$14.65M$47.33M$1.28M$112.88M
2024-09-30$4.89M$22.20M$12.69M$34.90M$0.00-$26.43M
2024-06-30$4.83M$21.14M(m)$34.17M$0.00-$25.70M
2024-03-31$4.22M$22.37M(m)$32.59M$0.00-$26.37M
2023-09-30$3.31M$20.27M(m)$30.54M$0.00-$24.54M
2023-06-30-$2.48M$20.55M(m)$30.78M$0.00-$30.65M
2023-03-31$5.15M$19.63M(m)$29.84M$0.00-$22.55M
2022-09-30$2.90M$20.11M(m)$30.05M$0.00-$26.11M
2022-06-30$3.23M$18.36M(m)$28.47M$0.00-$24.65M
2022-03-31$3.00M$18.31M(m)$27.80M$0.00-$24.65M
2021-09-30(m)$14.36M(m)$22.68M$0.00-$22.60M
2021-06-30(m)$14.10M(m)$22.03M$0.00-$21.97M
2021-03-31(m)$9.91M(m)$16.83M$0.00-$16.79M
2020-12-31(m)(m)(m)$14.59M(m)-$14.56M
2020-09-30(m)$8.11M(m)$13.71M$0.00-$13.68M
2020-06-30(m)$7.97M(m)$13.01M$0.00-$12.96M
2020-03-31(m)$7.21M(m)$11.73M$0.00-$11.04M
2019-12-31(m)(m)(m)$11.07M(m)-$10.16M
2019-09-30(m)$6.52M(m)$9.84M$0.00-$8.60M
2019-06-30(m)$6.02M(m)$8.45M$0.00-$7.82M
2019-03-31(m)$4.13M(m)$6.32M$0.00-$5.74M
2018-12-31(m)(m)(m)$4.54M(m)-$4.28M
2018-09-30(m)$2.23M(m)$3.32M$0.00-$3.32M
2018-06-30(m)$1.89M(m)$3.01M$0.00-$3.01M
2018-03-31(m)(m)(m)$1.91M(m)-$1.91M

Revenue and expense 6 month

Period endRevenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2026-06-30$15.55M$89.17M$45.23M$134.40M$0.00-$111.62M
2025-06-30$172.39M$58.53M$29.91M$88.45M$1.28M$89.40M
2024-06-30$9.05M$43.50M(m)$66.76M$0.00-$52.07M
2023-06-30$2.67M$40.18M(m)$60.62M$0.00-$53.20M
2022-06-30$6.23M$36.67M(m)$56.26M$0.00-$49.30M
2021-06-30(m)$24.01M(m)$38.86M$0.00-$38.76M
2020-06-30(m)$15.18M(m)$24.75M$0.00-$24.00M
2019-06-30(m)$10.16M(m)$14.77M$0.00-$13.56M
2018-06-30(m)$3.14M(m)$4.92M$0.00-$4.92M

Revenue and expense 9 month

Period endRevenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2025-09-30$183.02M$96.23M$45.94M$142.17M$0.00$51.05M
2024-09-30$13.94M$65.71M$35.95M$101.66M$0.00-$78.50M
2023-09-30$5.98M$60.45M(m)$91.17M$0.00-$77.74M
2022-09-30$9.14M$56.78M(m)$86.32M$0.00-$75.41M
2021-09-30(m)$38.37M(m)$61.54M$0.00-$61.36M
2020-09-30(m)$23.29M(m)$38.46M$0.00-$37.68M
2019-09-30(m)$16.68M(m)$24.61M$0.00-$22.16M
2018-09-30(m)$5.37M(m)$8.24M$0.00-$8.24M

Revenue and expense 12 month

Period endRevenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2025-12-31$184.42M$137.92M$67.09M$205.01M$0.00-$6.88M
2024-12-31$36.55M$89.13M$48.79M$137.93M(m)-$88.98M
2023-12-31$8.78M$82.23M(m)$123.55M(m)-$104.70M
2022-12-31$12.40M$77.84M(m)$116.76M(m)-$101.07M
2021-12-31(m)$54.17M(m)$86.06M(m)-$85.81M
2020-12-31(m)$32.20M(m)$53.04M(m)-$52.24M
2019-12-31(m)$23.76M(m)$35.68M(m)-$32.33M
2018-12-31(m)$8.37M(m)$12.78M(m)-$12.52M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Xeris Biopharma Holdings, Inc. (XERS)United States$1.632B-80.10
Rapport Therapeutics, Inc. (RAPP)United States$1.623B-14.56
Syndax Pharmaceuticals Inc (SNDX)United States$1.606B-8.82
Eton Pharmaceuticals, Inc. (ETON)United States$1.701B80.74
Kailera Therapeutics, Inc. (KLRA)United States$1.552B
ANAPTYSBIO, INC (ANAB)United States$1.546B-60.20
Innoviva, Inc. (INVA)United States$1.493B4.62
ArriVent BioPharma, Inc. (AVBP)United States$1.485B-10.25
Xencor Inc (XNCR)United States$1.776B-7.33
Septerna, Inc. (SEPN)United States$1.783B-63.01